SHP2 Inhibition Abrogates Adaptive Resistance to KRASG12C-Inhibition and Remodels the Tumor Microenvironment of KRAS-Mutant Tumors
C. Fedele, S. Li, K. W. Teng, C. Foster, D. Peng, H. Ran, P. Mita, M. Geer, T. Hattori, A. Koide, Y. Wang, K. H. Tang, J. Leinwand, W. Wang, B. Diskin, , B. G. Neel
This study shows that combining SHP2 inhibitors with KRASG12C inhibitors enhances efficacy in PDAC and NSCLC by overcoming resistance and remodeling the tumor microenvironment.
bioRxiv · May 30, 2020Cancer Biology